Kura Oncology, Inc. (KURA)

Kura Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	53.88	-	-	-	-
Cost of Revenue	155.35	-	-	-	-
Gross Profit	-101.46	-	-	-	-
Selling, General & Admin	77.11	50.57	47.05	46.54	31.5
Research & Development	14.62	115.24	92.81	84.72	60.4
Operating Expenses	91.73	165.8	139.87	131.26	91.9
Operating Income	-193.2	-165.8	-139.87	-131.26	-91.9
Interest Expense	-1.62	-1.55	-0.23	-0.41	-0.58
Interest & Investment Income	9.71	5.3	5.86	5.6	3.26
EBT Excluding Unusual Items	-185.11	-162.05	-134.23	-126.08	-89.22
Gain (Loss) on Sale of Investments	13.14	9.42	-1.61	-4.39	-0.41
Pretax Income	-171.97	-152.63	-135.84	-130.47	-89.63
Income Tax Expense	2.02	-	-	-	-
Net Income	-173.98	-152.63	-135.84	-130.47	-89.63
Net Income to Common	-173.98	-152.63	-135.84	-130.47	-89.63
Shares Outstanding (Basic)	86	73	67	66	53
Shares Outstanding (Diluted)	86	73	67	66	53
Shares Change (YoY)	17.66%	9.31%	0.96%	25.01%	26.54%
EPS (Basic)	-2.02	-2.08	-2.03	-1.97	-1.69
EPS (Diluted)	-2.02	-2.08	-2.03	-1.97	-1.69
Free Cash Flow	133.85	-124.99	-110.69	-105.7	-72
Free Cash Flow Per Share	1.55	-1.71	-1.65	-1.59	-1.36
Gross Margin	-188.30%	-	-	-	-
Operating Margin	-358.54%	-	-	-	-
Profit Margin	-322.89%	-	-	-	-
Free Cash Flow Margin	248.40%	-	-	-	-
EBITDA	-192.35	-164.96	-139.11	-130.7	-91.71
D&A For EBITDA	0.85	0.85	0.76	0.56	0.19
EBIT	-193.2	-165.8	-139.87	-131.26	-91.9
Revenue as Reported	53.88	-	-	-	-

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q